Becton Dickinson Discontinuing Glucose Monitor Development Program
This article was originally published in The Gray Sheet
Executive Summary
Becton Dickinson's decision not to introduce a stand-alone blood glucose monitoring product by year-end gives the company extra resources to focus further on its "strategic bullseye" represented by sharps protection, biosciences and insulin delivery.
You may also be interested in...
Becton Dickinson Signs Sharps Agreement But Predicts Disappointing Quarter
Becton Dickinson's safety engineered "sharps" program with Kaiser Permanente, announced June 16, signals the initial success of a strategy that is expected to carry the company out of its recent warnings of slower growth.
Federal Safe Needle Bill Mandates Use Of Sharps With Protective Features
Legislation introduced in the House May 20 by Reps. Pete Stark (D-Calif.) and Marge Roukema (R-N.J.) would amend the Occupational Safety and Health Administration's bloodborne pathogen standard to require that employers use needleless systems and sharps with engineered safety features to reduce the risk of accidental needlesticks among health care workers.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.